Virios Therapeutics Inc (VIRI) News

Agree, just hate how they say they have funding for the remainder of the year and then pull this..

Tbf its a small offering shouldn’t be a problem if that expect positive Long Covid trials

Same shit they pulled after hours last time when we were at 2.40.. Like a pinky wrapped in a NASDAQ cloak..

I gleaned that from CEO last call, my only concern is that put them at risk of an RS.

Sometimes you just have to show that you’re willing to do it all on your own.😎 VIRI LONG💰

We don’t know that for sure just yet.

No partnership :(

Minuscule to say the least. VIRI is a LONG TERM STOCK.😎💰

Virios Therapeutics Announces $2.1M Proposed Public Offering Of Common Stock

We have a pulse again! Let’s go TEAM VIRI😎💰

are we expecting the results from the long covid trial this summer or late in the 2nd Half of 2024?

Good move on your part😎👍 We are way overdue for a blockbuster PR💰

Been adding down at these levels too.


Was a fun trade before and I'm thinking we'll see another solid move at some point.
We shall see.


.35s

VIRI

Yeah! That one is pure insanity😳

Ok...time for this to pull a RNAZ for you all.

Well let’s hope you and your 🙀 don’t regret that decision. VIRI LONG💰

As my cat says .. meoowt

Keep selling!! I’m scooping up as much as I can.😎

You never know when that bombshell news could drop bud😎 Time will tell💰

They appear to keep stretching out a partnership :(

Conference call starts in 10 minutes.

ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), announced today that it will report first quarter 2024 financial results on Thursday, May 9, 2024 before the open of the financial markets. Management will also host a webcast and conference call on May 9, 2024 at 8:30 a.m. ET to discuss the results and provide a corporate update.
The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-506-0062 (domestic) or 973-528-0011 (international) and asking to be connected to the "Virios Therapeutics Conference Call" using the access code: 739495.

News out boys and girls

As of March 31, 2024, Virios Therapeutics' cash totaled $2.4 million. The Company believes it will have sufficient resources to fund operations into the fourth quarter of 2024.

Who wouldn't..

I would love for another company to take my shares from me at a nice premium….

I’d shit my pants with that kind of excitement😎🤣

Imagine we get a buyout or partnership this Thursday morning

Odd

Yeah I bought half those shares but they didn't show up for an hour

Yea I only see 4350 ish traded

Added a few thousand shares this am but it shows no volume..

Conference call May 9th Folks!!

ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that it will report first quarter 2024 financial results on Thursday, May 9, 2024 before the open of the financial markets. Management will also host a webcast and conference call on May 9, 2024 at 8:30 a.m. ET to discuss the results and provide a corporate update.

The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-506-0062 (domestic) or 973-528-0011 (international) and asking to be connected to the "Virios Therapeutics Conference Call" using the access code: 739495.

About Virios Therapeutics

Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (“FM”) and Long-COVID (“LC”). Overactive immune response related to activation of tissue resident herpesvirus has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel syndrome, LC, chronic fatigue syndrome and functional somatic syndromes, all of which are characterized by a waxing and waning manifestation of disease, often triggered by events which compromise the immune system. The Company’s lead development candidates are novel, proprietary, fixed dose combinations of an antiviral compound and celecoxib designed to synergistically suppress herpesvirus replication, with the end goal of reducing virally promoted disease symptoms. IMC-1 (fixed dosage combination of famciclovir and celecoxib) has been granted fast track designation by the FDA.

For more information, please visit www.virios.com.

Filing:

https://ir.stockpr.com/virios/sec-filings-email/content/0001558370-24-005761/tmb-20240618xdef14a.htm

No doubt.

Yeah man, and VIRI is definitely a buy and hold in my book.👍

That is how these small bio plays work though. You buy the stock expecting that they get bought out by the giant pharmaceuticals like Pfizer, Merck, etc. Virios could be bought out any day or not. But the more successful they are, the greater the chance (not that that is rocket science)

Hmmm a little action today

I’ll be right here waiting no matter how long it takes.😎

Right with you with those thoughts.

I truly believe it’s going to be worth the wait bud😎💰

Mr. Duncan, while at Pfizer he held several executive U.S. and international appointments, including President of Pfizer’s $2B Latin America Operations and SVP of Marketing. His operational teams had accountability for the launches of many pharmaceutical brands including Lipitor, Zoloft, Viagra, Celebrex, Aricept, Lyrica, Cimzia, Zithromax (ZPack), Diflucan, Sutent, Rebif and Vimpat.

Great color. I’ll be waiting. Thanks!

I truly believe it’s going to be worth the wait bud😎💰

Mr. Duncan, while at Pfizer he held several executive U.S. and international appointments, including President of Pfizer’s $2B Latin America Operations and SVP of Marketing. His operational teams had accountability for the launches of many pharmaceutical brands including Lipitor, Zoloft, Viagra, Celebrex, Aricept, Lyrica, Cimzia, Zithromax (ZPack), Diflucan, Sutent, Rebif and Vimpat.

It is time for this to take off….

On that note, I added again this am

I believe Greg Duncan Viri CEO mentioned the aim for the first Quarter 2024 to settle a partnership or funding opportunity, let us see if he delivers on time

$VIRI
They keep on highlighting this..are they foreshadowing or begging? 🤔 https://t.co/xtSKqZwBMF— Frank_Benedetto (@FrankieBstock) April 17, 2024

Their tweet has a common theme, I'm taking it as a hint

JAGX average was .07 it crossed .25

Which one? Congratulations

Now .45s added

Added .46s to me stash, these bios have a tendency to go ballistic without notice, like what one of mine did today

My Magic 8 Ball says hell yeah!😎💰